The proceeds from this financing round will be used towards the upcoming Phase 3 clinical trials for our lead candidate, CVT-301, an inhaled formulation of levodopa (L-dopa) being developed for rapid and reliable relief from debilitating motor fluctuations, known as OFF episodes, associated with Parkinson's disease (PD), as well as for the development of additional, early stage pipeline programs.

Company Information

Company Status

Acquired or Merged

Industry

Biopharmaceutical

Mailing Address

190 Everett Ave.
Chelsea, MA 02150
USA

Phone

617.660.4110

Website

www.civitastherapeutics.com

Email Address

[email protected]

Overview

Civitas is a pharmaceutical company focused on developing products with a clinically proven dry powder pulmonary delivery platform. The proprietary dry powder and device combination is unique in its ability to deliver a large, precise dose independent of inspiratory flow rate from a simple, passive device.

Profile

Social Media

Civitas Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Mark Iwicki

Chief Medical Officer

Martin Freed

Chief Scientific Officer

Rick Batycky

VP - Regulatory Affairs

Mary Taylor

VP - Sales

Bryan Stuart

Browse more venture capital transactions:

Prev: 8/25/2014: Zumigo venture capital transaction
Next: 8/25/2014: Symptomly venture capital transaction

Share this article

News on VC Transactions

We do our best to record funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary